Genzyme is reporting in a statement today that the global supply of Thyrogen will remain limited but improve for 2012. Genzyme anticipates meeting levels that approach 60-80% of that delivered in 2010 for the upcoming year. US supplies will likely be towards the upper end of this range.
Genzyme recommends that physicians seek to obtain Thyrogen for their patient through their usual suppliers but wait until it is secured before scheduling Thyrogen use in their patients.
No comments:
Post a Comment